Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| METTL14 Promotes Lipopolysaccharide-Induced Myocardial Damage via m6A-Dependent Stabilization of TRPM7 mRNA. | Int Heart J | 2024 | 39617501 | PubTator, text mining | PubMed |
| RNA methylation and breast cancer: insights into m6A, m7G and m5C. | Mol Biol Rep | 2024 | 39611867 | PubTator, text mining | PubMed |
| HNRNPH1 stabilizes FLOT2 mRNA in a non-canonical m6A-dependent manner to promote malignant progression in nasopharyngeal carcinoma. | Cell Oncol (Dordr) | 2024 | 39570559 | PubTator, text mining | PubMed |
| METTL14 suppresses the expression of YAP1 and the stemness of triple-negative breast cancer. | J Exp Clin Cancer Res | 2024 | 39563370 | PubTator, text mining | PubMed |
| METTL14-mediated m6A modification enhances USP22-ERα axis to drive breast cancer malignancy. | Pharmacol Res | 2024 | 39557350 | PubTator, text mining | PubMed |
| METTL14-mediated m6A modification upregulates HOXB13 expression to activate NF-κB and exacerbate cervical cancer progression. | Mol Cell Oncol | 2024 | 39534063 | PubTator, text mining | PubMed |
| METTL14 regulates inflammation in ulcerative colitis via the lncRNA DHRS4-AS1/miR-206/A3AR axis. | Cell Biol Toxicol | 2024 | 39528760 | PubTator, text mining | PubMed |
| METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma. | EMBO J | 2024 | 39528654 | PubTator, text mining | PubMed |
| Analysis of METTL14 expression in pancreatic cancer and adjacent tissues and its prognostic value for patient outcomes. | Clin Exp Med | 2024 | 39527301 | PubTator, text mining | PubMed |
| METTL14 Induced N6-Methyladenosine Modification of FOXP4 mRNA in HBV-HCC. | J Cancer | 2024 | 39513116 | PubTator, text mining | PubMed |
| RNAs m6A modification facilitates UVB-induced photoaging. | Heliyon | 2024 | 39512467 | PubTator, text mining | PubMed |
| UBR5 metabolically reprograms nasopharyngeal carcinoma cells to promote glycolysis and M2 polarization via SPLUNC1 signaling. | NPJ Precis Oncol | 2024 | 39501021 | PubTator, text mining | PubMed |
| METTL14-mediated m6A methylation regulates pathological retinal neovascularization by targeting autophagy. | Exp Cell Res | 2024 | 39461405 | PubTator, text mining | PubMed |
| Regulation of renal ischemia-reperfusion injury and tubular epithelial cell ferroptosis by pparγ m6a methylation: mechanisms and therapeutic implications. | Biol Direct | 2024 | 39444036 | PubTator, text mining | PubMed |
| Regulation of m6A (N6-Methyladenosine) methylation modifiers in solid cancers. | Funct Integr Genomics | 2024 | 39438339 | PubTator, text mining | PubMed |
| METTL3-mediated m6A modification enhances lncRNA H19 stability to promote endothelial cell inflammation and pyroptosis to aggravate atherosclerosis. | FASEB J | 2024 | 39432244 | PubTator, text mining | PubMed |
| METTL14-mediated m6A modification upregulated SOCS3 expression alleviates thyroid cancer progression by regulating the JAK2/STAT3 pathway. | Mol Cell Probes | 2024 | 39413935 | PubTator, text mining | PubMed |
| Post-Translational Modifications of RNA-Modifying Proteins in Cellular Dynamics and Disease Progression. | Adv Sci (Weinh) | 2024 | 39377984 | PubTator, text mining | PubMed |
| Exosomal non-coding RNAs: Emerging insights into therapeutic potential and mechanisms in bone healing. | J Tissue Eng | 2024 | 39371940 | PubTator, text mining | PubMed |
| Stabilization of RRBP1 mRNA via an m6A-dependent manner in prostate cancer constitutes a therapeutic vulnerability amenable to small-peptide inhibition of METTL3. | Cell Mol Life Sci | 2024 | 39367907 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=22